{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:38:04Z","timestamp":1794451084952,"version":"4.9.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Serum uric acid (SUA) and hyperuricaemia have re-emerged as determinants of cardiovascular (CV) risk beyond gout. This review integrates epidemiological, Mendelian randomization (MR), and pharmacological evidence to define the role of SUA and urate-lowering therapy (ULT) in contemporary CV pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We synthesized population-based studies, MR and drug-target MR analyses, and randomized trials of xanthine oxidase inhibitors (XOIs), uricosurics\/URAT1 inhibitors, biologic uricases, and CV drugs with urate-modifying effects. Hyperuricaemia is prevalent and rising, often closely accompanying obesity, hypertension, diabetes, and chronic kidney disease (CKD). Higher SUA correlates with coronary artery disease, heart failure, stroke, cardio\u2013renal\u2013metabolic syndromes, and mortality, with non-linear risk relationships and sex- and age-specific thresholds. Mendelian randomization suggests a modest causal contribution of genetically elevated SUA to blood pressure, coronary disease, and advanced CKD, partly mediated via haemodynamic, renal, and inflammatory pathways. Pharmacologically, XOIs, URAT1 inhibitors, and uricases differ in kinetics and safety profiles. However, large trials and real-world cohorts show no consistent reduction in CV events when ULT is added to guideline-directed therapy in asymptomatic hyperuricaemia, stable ischaemic heart disease, chronic heart failure, or CKD. Observational data suggest that long-term, adequately dosed XOIs and high cumulative uricosuric exposure may reduce coronary risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum uric acid is a cardio\u2013renal\u2013metabolic biomarker and a plausible therapeutic target in selected cardio\u2013renal\u2013metabolic phenotypes. However, evidence does not support routine ULT for CV prevention in asymptomatic hyperuricaemia. Urate-lowering therapy should remain focused on gout and symptomatic hyperuricaemia, with phenotype-guided strategies to identify patients with asymptomatic hyperuricemia most likely to benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag042","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:30:49Z","timestamp":1781613049000},"page":"410-420","source":"Crossref","is-referenced-by-count":3,"title":["Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio\u2013renal\u2013metabolic risk modulation"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna , Via Massarenti 9, Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna , Via Massarenti 9, Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical Pharmacology, Medical Faculty, Ataturk University , Erzurum 25240 ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F G","family":"Cicero","sequence":"additional","affiliation":[{"name":"Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna , Via Massarenti 9, Bologna 40138 ,","place":["Italy"]},{"name":"Cardiovascular Medicine Unit, Heart, Chest and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Via Massarenti 9, Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026081706514646700_pvag042-B1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023","volume":"86","author":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081706514646700_pvag042-B2","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.jacl.2024.07.001","article-title":"Addressing residual risk beyond statin therapy: new targets in the management of dyslipidaemias-a report from the European Society of Cardiology Cardiovascular Round Table","volume":"18","author":"Mach","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026081706514646700_pvag042-B3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026081706514646700_pvag042-B4","doi-asserted-by":"crossref","first-page":"1577952","DOI":"10.3389\/fcvm.2025.1577952","article-title":"A systematic review of the connection between serum uric acid levels and the risk of cardiovascular disease","volume":"12","author":"Wang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"2026081706514646700_pvag042-B5","doi-asserted-by":"crossref","first-page":"e043917","DOI":"10.1136\/bmjopen-2020-043917","article-title":"Temporal trends in hyperuricemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study","volume":"11","author":"Wan","year":"2021","journal-title":"BMJ Open"},{"key":"2026081706514646700_pvag042-B6","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1038\/s41598-020-64587-z","article-title":"Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort","volume":"10","author":"Zitt","year":"2020","journal-title":"Sci Rep"},{"key":"2026081706514646700_pvag042-B7","doi-asserted-by":"crossref","first-page":"e0198197","DOI":"10.1371\/journal.pone.0198197","article-title":"Temporal trends in hyperuricemia in the Irish health system from 2006\u20132014: a cohort study","volume":"13","author":"Kumar","year":"2018","journal-title":"PLoS One"},{"key":"2026081706514646700_pvag042-B8","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.3390\/ijms21114066","article-title":"Hyperuricemia and hypertension, coronary artery disease, kidney disease: from concept to practice","volume":"21","author":"Gaubert","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026081706514646700_pvag042-B9","doi-asserted-by":"crossref","first-page":"21808","DOI":"10.1038\/s41598-024-72527-4","article-title":"Association of serum uric acid to all-cause and cardiovascular mortality in patients with cardiovascular disease","volume":"14","author":"Song","year":"2024","journal-title":"Sci Rep"},{"key":"2026081706514646700_pvag042-B10","doi-asserted-by":"crossref","first-page":"e038723","DOI":"10.1161\/JAHA.124.038723","article-title":"Exploration of the interrelationship between serum uric acid, gout, and cardiac, renal, and metabolic conditions in middle aged and older people","volume":"14","author":"Han","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026081706514646700_pvag042-B11","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.3390\/jcm14227922","article-title":"Hyperuricemia as an early indicator of cardiovascular risk in the general population","volume":"14","author":"Al-Azem","year":"2025","journal-title":"J Clin Med"},{"key":"2026081706514646700_pvag042-B12","doi-asserted-by":"crossref","first-page":"e0337091","DOI":"10.1371\/journal.pone.0337091","article-title":"Association of hyperuricemia with coronary heart disease and other cardiovascular outcomes: a systematic review and dose-response meta-analysis","volume":"20","author":"Lyu","year":"2025","journal-title":"PLoS One"},{"key":"2026081706514646700_pvag042-B13","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.ejim.2025.07.028","article-title":"Crystal clear\u2014Part I: The role of uric acid in cardiorenal disease","volume":"142","author":"Borghi","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2026081706514646700_pvag042-B14","doi-asserted-by":"crossref","first-page":"106554","DOI":"10.1016\/j.ejim.2025.106554","article-title":"Crystal clear\u2014Part II: The role of uric acid in cardiorenal disease","volume":"142","author":"Borghi","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2026081706514646700_pvag042-B15","doi-asserted-by":"crossref","first-page":"104107","DOI":"10.1016\/j.numecd.2025.104107","article-title":"Trajectory of body shape in early and middle life and hyperuricemia: an observational study integrating Mendelian randomization analysis","volume":"35","author":"Zhang","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026081706514646700_pvag042-B16","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2147\/DMSO.S510384","article-title":"The effects of specific gut microbiota on hyperuricemia\u2014a Mendelian randomization analysis and clinical validation","volume":"18","author":"Aikepa","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026081706514646700_pvag042-B17","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1097\/JS9.0000000000003948","article-title":"Biological aging and gout risk in hyperuricemia: a UK biobank cohort study","volume":"112","author":"Li","year":"2025","journal-title":"Int J Surg"},{"key":"2026081706514646700_pvag042-B18","doi-asserted-by":"crossref","first-page":"26675","DOI":"10.1038\/s41598-024-76970-1","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients","volume":"14","author":"Lv","year":"2024","journal-title":"Sci Rep"},{"key":"2026081706514646700_pvag042-B19","doi-asserted-by":"crossref","first-page":"e030625","DOI":"10.1161\/JAHA.123.030625","article-title":"Uric acid levels, number of standard modifiable cardiovascular risk factors, and prognosis in patients with coronary artery disease: a large cohort study in Asia","volume":"12","author":"Cui","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026081706514646700_pvag042-B20","doi-asserted-by":"crossref","first-page":"2496514","DOI":"10.1080\/10641963.2025.2496514","article-title":"Serum uric acid levels as a causal factor in hypertension: insights from Mendelian randomization analysis","volume":"47","author":"Xu","year":"2025","journal-title":"Clin Exp Hypertens"},{"key":"2026081706514646700_pvag042-B21","doi-asserted-by":"crossref","first-page":"e44135","DOI":"10.1097\/MD.0000000000044135","article-title":"A Mendelian randomization study of serum uric acid in metabolic and cardiovascular risk in East Asian populations","volume":"104","author":"Li","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"2026081706514646700_pvag042-B22","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/biomedicines13081838","article-title":"Causal relationship between serum uric acid and atherosclerotic disease: a Mendelian randomization and transcriptomic analysis","volume":"13","author":"Wang","year":"2025","journal-title":"Biomedicines"},{"key":"2026081706514646700_pvag042-B23","first-page":"100587","article-title":"Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis","volume":"57","author":"Luo","year":"2025","journal-title":"Am Heart J Plus"},{"key":"2026081706514646700_pvag042-B24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"key":"2026081706514646700_pvag042-B25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejim.2020.10.001","article-title":"Serum uric acid and mortality thresholds among men and women in the Irish health system: a cohort study","volume":"84","author":"Browne","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2026081706514646700_pvag042-B26","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1038\/s41598-020-63134-0","article-title":"Association between serum uric acid levels and mortality: a nationwide community-based cohort study","volume":"10","author":"Konta","year":"2020","journal-title":"Sci Rep"},{"key":"2026081706514646700_pvag042-B27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s10038-023-01168-8","article-title":"GLUT9 as a potential drug target for chronic kidney disease: drug target validation by a Mendelian randomization study","volume":"68","author":"Ueda","year":"2023","journal-title":"J Hum Genet"},{"key":"2026081706514646700_pvag042-B28","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s11255-025-04594-z","article-title":"The effects of GLUT9 and URAT1 inhibitors on cardiovascular diseases: a drug-targeted Mendelian randomization study","volume":"57","author":"Xu","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026081706514646700_pvag042-B29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512178","article-title":"Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients","volume":"30","author":"Cicero","year":"2021","journal-title":"Med Princ Pract"},{"key":"2026081706514646700_pvag042-B30","doi-asserted-by":"crossref","first-page":"582680","DOI":"10.3389\/fphar.2020.582680","article-title":"Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective","volume":"11","author":"Yu","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026081706514646700_pvag042-B31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40265-019-01081-5","article-title":"Cardiovascular disease in gout and the protective effect of treatments including urate-lowering therapy","volume":"79","author":"Gupta","year":"2019","journal-title":"Drugs"},{"key":"2026081706514646700_pvag042-B32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","article-title":"Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review","volume":"83","author":"Terkeltaub","year":"2023","journal-title":"Drugs"},{"key":"2026081706514646700_pvag042-B33","doi-asserted-by":"crossref","first-page":"152801","DOI":"10.1016\/j.semarthrit.2025.152801","article-title":"Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: a modeling analysis of literature aggregate data","volume":"74","author":"Cai","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026081706514646700_pvag042-B34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2026081706514646700_pvag042-B35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamainternmed.2024.0376","article-title":"Sodium-glucose cotransporter-2 inhibitors vs sulfonylureas for gout prevention among patients with type 2 diabetes receiving metformin","volume":"184","author":"McCormick","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026081706514646700_pvag042-B36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.mayocp.2022.02.027","article-title":"Lowering and raising serum urate levels: off-label effects of commonly used medications","volume":"97","author":"Leung","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2026081706514646700_pvag042-B37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jjcc.2023.04.005","article-title":"High- versus low-dose losartan and uric acid: an analysis from HEAAL","volume":"82","author":"Ferreira","year":"2023","journal-title":"J Cardiol"},{"key":"2026081706514646700_pvag042-B38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/dc25-1713","article-title":"Gout-related medication use after initiating sodium-glucose cotransporter 2 inhibitors in patients with gout and type 2 diabetes: population-based target trial emulation studies","volume":"49","author":"McCormick","year":"2026","journal-title":"Diabetes Care"},{"key":"2026081706514646700_pvag042-B39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s11845-021-02761-6","article-title":"Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in type 2 diabetic patients with established coronary heart disease: the SUPER GATE study","volume":"191","author":"Bilgin","year":"2022","journal-title":"Ir J Med Sci"},{"key":"2026081706514646700_pvag042-B40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamacardio.2024.2435","article-title":"Verinurad plus allopurinol for heart failure with preserved ejection fraction: the AMETHYST randomized clinical trial","volume":"9","author":"Kitzman","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026081706514646700_pvag042-B41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41371-024-00906-5","article-title":"Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST","volume":"38","author":"Macdonald","year":"2024","journal-title":"J Hum Hypertens"},{"key":"2026081706514646700_pvag042-B42","doi-asserted-by":"crossref","first-page":"e092522","DOI":"10.1136\/bmjopen-2024-092522","article-title":"Allopurinol use and risk of acute coronary syndrome in gout patients: a population-based cohort study in Sweden","volume":"15","author":"Drivelegka","year":"2025","journal-title":"BMJ Open"},{"key":"2026081706514646700_pvag042-B43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2017.02.013","article-title":"Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: a population-based study","volume":"233","author":"Lin","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026081706514646700_pvag042-B44","first-page":"1","article-title":"Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation","volume":"28","author":"Mackenzie","year":"2024","journal-title":"Health Technol Assess"},{"key":"2026081706514646700_pvag042-B45","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"key":"2026081706514646700_pvag042-B46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00380-024-02448-9","article-title":"Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study","volume":"40","author":"Yokota","year":"2025","journal-title":"Heart Vessels"},{"key":"2026081706514646700_pvag042-B47","doi-asserted-by":"crossref","first-page":"e099442","DOI":"10.1136\/bmjopen-2025-099442","article-title":"Effects of febuxostat on heart failure patients with asymptomatic hyperuricemia: a retrospective cohort study","volume":"15","author":"Long","year":"2025","journal-title":"BMJ Open"},{"key":"2026081706514646700_pvag042-B48","doi-asserted-by":"crossref","first-page":"e70149","DOI":"10.1111\/nep.70149","article-title":"Allopurinol versus febuxostat use and the risk of cardiovascular disease in people with chronic kidney disease: a new-user active comparator cohort study","volume":"30","author":"Inoue","year":"2025","journal-title":"Nephrology (Carlton)"},{"key":"2026081706514646700_pvag042-B49","first-page":"e70351","article-title":"Association between febuxostat use and the incidence of cardiovascular events, mortality, and kidney events in patients with chronic kidney disease compared to allopurinol: a study using a Japanese nationwide database","volume":"16","author":"Otani","year":"2024","journal-title":"Cureus"},{"key":"2026081706514646700_pvag042-B50","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s10067-023-06710-9","article-title":"Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia","volume":"42","author":"Hashimoto","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026081706514646700_pvag042-B51","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00296-022-05139-8","article-title":"Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014\u20132017","volume":"42","author":"Weisshaar","year":"2022","journal-title":"Rheumatol Int"},{"key":"2026081706514646700_pvag042-B52","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"2026081706514646700_pvag042-B53","doi-asserted-by":"crossref","first-page":"1759720X221116409","DOI":"10.1177\/1759720X221116409","article-title":"Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout","volume":"14","author":"Eun","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026081706514646700_pvag042-B54","doi-asserted-by":"crossref","first-page":"e28683","DOI":"10.1097\/MD.0000000000028683","article-title":"Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: a CONSORT-compliant randomized controlled trial","volume":"101","author":"Ma","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026081706514646700_pvag042-B55","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/j.numecd.2021.09.011","article-title":"Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs","volume":"31","author":"Fogacci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026081706514646700_pvag042-B56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa1710895","article-title":"Febuxostat versus allopurinol in patients with gout and cardiovascular disease","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081706514646700_pvag042-B57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/biomedicines13051022","article-title":"Identification of therapeutic targets for hyperuricemia: systematic genome-wide Mendelian randomization and colocalization analysis","volume":"13","author":"Chen","year":"2025","journal-title":"Biomedicines"},{"key":"2026081706514646700_pvag042-B58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf"},{"key":"2026081706514646700_pvag042-B59","doi-asserted-by":"crossref","first-page":"102207","DOI":"10.1016\/j.jacadv.2025.102207","article-title":"Association of uric acid-lowering therapies on gout frequency with bempedoic acid: clinical insights from CLEAR outcomes","volume":"4","author":"Ray","year":"2025","journal-title":"JACC Adv"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag042\/68542840\/pvag042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/5\/410\/68542840\/pvag042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/5\/410\/68542840\/pvag042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:52:01Z","timestamp":1786963921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/5\/410\/8709977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,17]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag042","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,17]]}}}